3 years ago

Case definitions for inclusion and analysis of endpoints in clinical trials for NASH through the lens of regulatory science.

Laurent Castera, Manal F Abdelmalek, David Kleiner, Stephen A Harrison, Katherine Greene, M Shadab Siddiqui, Veronica Miller, Elmer Schabel, Scott Friedman, Quentin M Anstee, Pierre Bedossa, Vlad Ratziu, Lara Dimick-Santos, Brent A Neuschwander-Tetri, Arun J Sanyal, Sophie Megnien
Nonalcoholic steatohepatitis (NASH) is an important cause of liver-related morbidity and mortality. There are no approved therapies and the results of clinical trials have been difficult to compare due to inconsistent definitions of relevant disease parameters in patients with NASH. The natural course of the disease has not been rigorously characterized particularly with respect to the contributions of underlying obesity, type 2 diabetes and other comorbidities and the treatments provided to these comorbidities. Efforts to perform analyses of pooled data are limited by heterogeneous case definitions used across studies to define disease states. There remains a major unmet need in the field to develop standardized definitions for populations for interventional trials. Such definitions are expected to impact how endpoints for clinical trials are constructed. The Liver Forum is a multi-stakeholder effort including US and European regulatory agencies, academic investigators, professional and patient representative organizations and industry to catalyze therapeutic development for NASH by developing potential solutions to barriers to development. The Case Definitions Working Group was established by The Liver Forum to evaluate the validity of case definitions for populations to be included in clinical trials for NASH from a regulatory science perspective. Based on such analyses, specific recommendations are provided noting the strengths and weaknesses of the case definitions along with knowledge gaps that require additional study. This article is protected by copyright. All rights reserved.

Publisher URL: http://doi.org/10.1002/hep.29607

DOI: 10.1002/hep.29607

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.